Incadronic acid

A bisphosphonate medication used in the treatment of bone diseases

Incadronic acid
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Incadronic acid is a bisphosphonate medication primarily used in the treatment of various bone diseases, including osteoporosis and Paget's disease of bone. It functions by inhibiting the resorption of bone, thereby maintaining or increasing bone density.

Mechanism of Action

Incadronic acid works by binding to hydroxyapatite found in bone, inhibiting the action of osteoclasts, which are the cells responsible for bone resorption. This action helps to prevent the loss of bone mass and can lead to an increase in bone density over time.

Pharmacokinetics

After administration, incadronic acid is absorbed into the bloodstream and preferentially localizes to bone tissue. The drug has a high affinity for bone mineral, which contributes to its long duration of action. The elimination of incadronic acid occurs primarily through the kidneys.

Clinical Uses

Incadronic acid is used in the management of:

• Osteoporosis: To prevent fractures by increasing bone density.
• Paget's disease of bone: To regulate bone remodeling and reduce bone pain.
• Hypercalcemia of malignancy: To lower elevated calcium levels in the blood associated with cancer.

Side Effects

Common side effects of incadronic acid include:

• Gastrointestinal discomfort
• Esophagitis
• Hypocalcemia

Less common but serious side effects can include osteonecrosis of the jaw and atypical femoral fractures.

Administration

Incadronic acid is typically administered orally, but the specific dosage and frequency depend on the condition being treated and the patient's overall health status.

Related pages

• Bisphosphonate
• Osteoporosis
• Paget's disease of bone